Awareness of the recent advances in therapeutic options and the requirement to correctly identify the HER2-low group of breast tumours is particularly relevant as the boundaries between 0 and 1+ scores, as highlighted in the current study, are less clear. Here, ERBB2 is linked to breast neoplasm.